The prevalence and disease burden of severe eosinophilic asthma in Japan-Reference-Cited by-同舟云学术

The prevalence and disease burden of severe eosinophilic asthma in Japan

Published:2019-03-01 Issue:11 Volume:56 Page:1147-1158
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Nagasaki Tadao¹,Sato Keiko²,Kume Naoto³,Oguma Tsuyoshi¹⁴,Sunadome Hironobu¹,Ito Isao¹,Izuhara Yumi¹,Okamoto Kazuya⁵,Kobayashi Shinji³,Ohno Tomoya²,Mizukami Akiko²,Kobayashi Akihiro²,Kaise Toshihiko²,Kuroda Tomohiro⁵,Mishima Michiaki¹,Matsumoto Hisako¹

Affiliation:

1. Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan;

2. Development & Medical Affairs Division, GSK K.K., Tokyo, Japan;

3. Department of EHR, Graduate School of Medicine, Kyoto University, Kyoto, Japan;

4. Department of Community Medicine Supporting System, Graduate School of Medicine, Kyoto University, Kyoto, Japan;

5. Division of Medical Information Technology and Administration Planning, Kyoto University Hospital, Kyoto, Japan

Funder

GSK

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Link

https://tandfonline.com/doi/pdf/10.1080/02770903.2018.1534967

Reference27 articles.

1. Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma

2. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

3. Asthma Control and Management Changes in Japan: Questionnaire Survey

4. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

5. Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asthma exacerbations and airway redox imbalance under type 2 inflammatory conditions;Respiratory Investigation;2024-11

2. Uncontrolled mild‐to‐moderate asthma may not be mild or moderate, or even asthma: The benefits of early phenotyping;Respirology;2024-07-11

3. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy;BMC Pulmonary Medicine;2024-03-21

4. PRevalence of the Eosinophilic Phenotype Among SeveRE asthma patients in Lebanon: results of the PREPARE study;Allergy, Asthma & Clinical Immunology;2023-09-08

5. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy;2023-08-29